UAEM - Licensing and patenting practices of COVID-19 technologies

Sarai Keestra made this Freedom of Information request to University of Reading

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Reading,

For the purpose of clarity, please adhere to the following definitions when answering these questions:

Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...

Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Can you release your internal strategy regarding licensing and patenting of COVID-19 related health technologies?

Q2. Does the institution have a formal policy on licensing and patenting of COVID-19 related technologies? If yes, please provide a link or PDF to the relevant policy document.

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since the start of the pandemic?

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted.

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (https://opencovidpledge.org/) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic? If yes, please specify.

Q7. Is the institution considering the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

IMPS, University of Reading

Dear Ms Keestra,

This is to acknowledge receipt of your request for information below and to let you know it is being processed.

We'll get back to you as soon as we can, but in any case within 20 working days from 25/10/2020.

In the meantime, if you wish to add any further details or check on progress, please reply to this message, quoting the reference number 'IMPS#02915', so that we can track your input and respond promptly.

Yours sincerely,

Sinead Latham

Information Management & Policy Services (IMPS), University of Reading, Whiteknights, Reading, RG6 6AH
t: +44 (0)118 378 8981 www.reading.ac.uk/foia

show quoted sections

IMPS, University of Reading

Dear Ms Keestra,  

 

We have completed the compilation of information in response to your
request.

 

We can confirm that we do not hold the information specified in your
request. Our responses are given below each limb of your request in blue.

 

 

***************** FOI RESPONSE ***************

 

Q1. Can you release your internal strategy regarding licensing and
patenting of COVID-19 related health technologies?

 

No information held. The University does not hold an “internal strategy
regarding licensing and patenting of COVID-19 related health
technologies”.

 

Q2. Does the institution have a formal policy on licensing and patenting
of COVID-19 related technologies? If yes, please provide a link or PDF to
the relevant policy document.

 

No

Q3. Has the university considered updating their strategy regarding the
licensing and patenting of health technologies since the start of the
pandemic?

 

No information held. Under FOIA we are not required to provide opinions or
comments or answer speculative questions where the information requested
is not clearly described and/or is neither held nor already recorded.    

Q4. Please provide an Excel spreadsheet with headings as displayed below
with all the COVID-19 related health technologies LICENSED by the
university AND specify which countries they were licensed in AND specify
whether they are exclusive or non-exclusive licenses.

 

Health Technology Licensed | Country of Licensing | Type of License
(Exclusive or Non-Exclusive)

 

No information held. There has not been any ‘COVID-19 related health
technologies LICENSED by the university’.

 

Q5. Please provide a list of patents granted to your organization for any
COVID-19 related health technologies listed by patent family, indicating
countries/regions in which the patent has been granted.

 

No information held. There has not been any ‘patents granted to [the
university] for any COVID-19 related health technologies’.

 

Q6. Does the institution have any plans on signing up to the Open-COVID
pledge
([1]https://eur03.safelinks.protection.outlo...)
or any similar initiative that seeks to minimise intellectual property
rights barriers during the COVID-19 pandemic? If yes, please specify.

 

No information held. Under FOIA we are not required to provide opinions or
comments or answer speculative questions where the information requested
is not clearly described and/or is neither held nor already recorded.    

Q7. Is the institution considering the licensing of COVID-19 related
health technologies to the Covid Technology Access Pool (C-TAP) or the
Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

 

No information held. Under FOIA we are not required to provide opinions or
comments or answer speculative questions where the information requested
is not clearly described and/or is neither held nor already recorded.    

********************** END *************

  

We are required to include details of our complaints procedures, including
your rights to apply to the Information Commissioner.  The procedure is
detailed in our Freedom of Information and Environmental Information
Regulations policy on the web at
[2]www.reading.ac.uk/freedom-of-information-policy

 

If we are unable to resolve any complaint, you can complain to the
Information Commissioner, the independent body who oversees the access to
information regimes: [3]https://ico.org.uk/make-a-complaint/ 

 

 

Yours sincerely, 

 

Sinead Latham

Information Compliance Officer

 

Information Management & Policy Services (IMPS), University of Reading,
Whiteknights, Reading, RG6 6AH

[4][University of Reading request email]    t: +44 (0)118 378 8981   
[5]www.reading.ac.uk/foia

show quoted sections